title: A Revolution in Treatment for Hepatitis C Infection: Mitigating the Budgetary Impact.
abstract: In a Perspective accompanying Hill and colleagues, Elliot Marseille and James Kahn compare the history of pricing and availability of ART for HIV with that of the new HCV drugs and discuss strategies for providing treatment in LMIC even in the face of high costs.
authors.affiliation: Health Strategies International, Oakland, California, United States of America.
authors.forename: Elliot
authors.initials: E
authors.lastname: Marseille
authors.affiliation: Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, California, United States of America.
authors.forename: James G
authors.initials: JG
authors.lastname: Kahn
mesh_terms: D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D006526:Hepatitis C / Q000188:drug therapy / Q000191:economics*; D006801:Humans
chemical_list: D000998:Antiviral Agents